Joshi Alumkal, MD

Joshi Alumkal, MD, discusses treatment options for patients with metastatic castrate-resistant prostate cancer harboring homologous recombination deficient alterations, including PARP inhibitors.

Joshi Alumkal, MD, discusses the use of triplet therapy in prostate cancer.

Joshi Alumkal, MD, discusses the effects of the phase 3 ARESENS trial on the treatment of metastatic hormone-sensitive prostate cancer.